Evidence map›Paper›PMID 35204680›Full record

ArticleBiomolecules2022

PEPscan: A Broad Spectrum Approach for the Characterization of Protein-Binder Interactions?

Angelita Rebollo, Louise Fliedel, Pierre Tuffery

Abstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Angelita RebolloUniversité de Paris, INSERM U 1267, CNRS U 8258, UTCBS, F-75006 Paris, France.
Louise FliedelUniversité de Paris, INSERM U 1267, CNRS U 8258, UTCBS, F-75006 Paris, France.ORCID 0000-0001-8838-4704
Pierre TufferyUnité de Biologie Fonctionnelle et Adaptative, Université de Paris, CNRS U 8251, INSERM U 1133, F-75013 Paris, France.ORCID 0000-0003-1033-9895

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a previous study, we have shown that PEPscan can provide a cheap and rapid means to identify candidate interfering peptides (IPs), i.e., peptides able to disrupt a target protein-protein interaction. PEPscan was shown to be effective in identifying a limited number of candidate IPs specific to the target interaction. Here, we investigate the results of 14 new PEPscan experiments for protein complexes of known 3D structures. We show that for almost all complexes, PEPscan is able to identify candidate IPs that are located at the protein-protein interface. The information it provides about the binding site seems, however, too ambiguous to be exploited in a simple manner to assist the modeling of protein complexes. Moreover, these candidates are associated with false positives. For these, we suggest they could correspond to non-specific binders, which leaves room for further optimization of the PEPscan protocol. Another unexpected advance comes from the observation of the applicability of PEPscan for polysaccharides and labeled peptides, suggesting that PEPscan could become a large spectrum approach to investigate protein-binder interactions, the binder not necessarily being a protein.

Indexed as

PeptidesProteinsBinding SitesBiophysical PhenomenaPeptidesProteinsPEPscanprotein-peptide interactionsprotein-polysaccharide interactionsprotein-protein interaction

Identifiers

PMID35204680
PMCPMC8961561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.